The BioPharm Brief: Hormones, Metabolism, Momentum

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we're looking at new clinical data across three therapeutic areas, chronic hypoparathyroidism, metabolic disease, and facioscapulohumeral muscular dystrophy, or FSHD. The updates underscore continued efforts to develop longer-acting therapies and disease-modifying treatments for conditions with significant unmet need.

First, MBX Biosciences reported one-year data for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for chronic hypoparathyroidism. In the ongoing open-label extension study, 57% of evaluable patients maintained responder status at one year, while serum calcium levels remained within the normal range and kidney function measures improved. The company says the findings support advancement into a Phase 3 trial, which remains on track to begin later this year.

Next, Gan & Lee Pharmaceuticals announced positive results from multiple studies evaluating insulin ludefen and the GLP-1 receptor agonist bofanglutide. Across Type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease, the candidates met key clinical endpoints, including improvements in glycemic control, weight reduction, and liver fat content. The results add to growing competition in the rapidly evolving metabolic disease market.

Finally, Novartis reported positive biomarker data from the Phase 1/2 FORTITUDE study of delpacibart braxlosiran, an investigational antibody oligonucleotide conjugate for FSHD. The therapy met its primary and key secondary endpoints, demonstrating reductions in biomarkers associated with DUX4 activity and muscle damage. Novartis plans to discuss the data with regulators while continuing enrollment in its Phase 3 study.

Those are today's highlights shaping the future of endocrine, metabolic, and neuromuscular medicine.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• MBX's canvuparatide delivered sustained one-year results in chronic hypoparathyroidism and remains on track for phase 3.
  
• Gan & Lee reported positive metabolic disease data across diabetes, obesity, and liver disease programs.
  
• Novartis advanced its FSHD program with positive biomarker results supporting ongoing Phase 3 development.